Beta-glucan-induced trained innate immunity mediates antitumor efficacy in the mouse lung
作者
Matthew P. Alexander,Steven Fiering,Gary R. Ostroff,Robert A. Cramer,David W. Mullins
出处
期刊:Journal of Immunology [American Association of Immunologists] 日期:2016-05-01卷期号:196 (1_Supplement): 142.24-142.24被引量:3
标识
DOI:10.4049/jimmunol.196.supp.142.24
摘要
Abstract The innate arm of the vertebrate immune system has classically been regarded as nonspecific and lacking the capacity for adaptive responses, in contrast to the adaptive arm defined by its robust memory responses. Recent high impact work has demonstrated enhanced non-specific responses of innate immune cells to pathogens and malignancy after priming with the fungal cell wall component beta-glucan, a phenomenon termed trained innate immunity (TII). In a pathogen model, the training effect was mediated by epigenetic modifications underlying a metabolic shift to mTOR- and HIF1α-mediated aerobic glycolysis. To investigate whether these same pathways play a role in non-specific enhancement of antitumor responses, we assessed beta-glucan-mediated anti-tumor efficacy in a mouse model of metastatic melanoma. We observed that systemic pretreatment with a particulate beta-glucan significantly diminished the growth of metastatic-like B16 melanoma in the lungs, but not initial tumor cell engraftment. Further, lungs in beta-glucan treated animals had a robust myeloid immune infiltrate, particularly neutrophils and monocytes. Interestingly, initial studies demonstrate that tumor suppressed HIF1α expression, and beta-glucan pretreatment prevented this suppression. These results are consistent with beta-glucan induction of TII, leading to suppression of cancer growth. By extension, TII may modulate the immunogenic nature of the tumor microenvironment, thereby acting as an adjuvant to enhance the efficacy of existing therapies.